LSTA — Lisata Therapeutics, Inc.

Lisata Therapeutics (LSTA) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Operating Expenses: Totaled $4.4 million for Q3 2025, down from $5.3 million in Q3 2024 (17.3% decrease).
  • R&D Expenses: Approximately $2 million, a 22.9% decrease year-over-year, attributed to reduced spending in various areas.
  • G&A Expenses: Approximately $2.5 million, down 12.1% from the prior year.
• Net Loss: Reported at $4.2 million for Q3 2025, compared to $4.9 million in Q3 2024.
• Cash Position: As of September 30, 2025, cash and cash equivalents were approximately $19 million, projected to support operations into Q1 2027.

2. Strategic Updates and Business Highlights

• Certepetide Development: Positive preliminary results from multiple trials (ASCEND, BOLSTER, CENDIFOX) indicate potential efficacy in treating advanced solid tumors.
• Strategic Alliances:
  • Partnership with GATC Health to leverage AI for drug discovery.
  • Nonexclusive global license agreement with Catalent for the use of certepetide in their SMARTag ADC technology.
• Regulatory Progress: Certepetide has secured multiple special designations from the FDA and EMA.
• Upcoming Milestones: Anticipated data readouts from ongoing trials and preparations for a Phase III trial contingent on capital acquisition.

3. Forward Guidance and Outlook

• Lisata expects a data-rich period in the coming quarters with several key milestones.
• The company is preparing for a Phase III trial for certepetide, contingent on securing funding through partnerships or licensing agreements.

4. Bad News, Challenges, or Points of Concern

• Market Reaction: Despite positive clinical data, the stock price has not reacted favorably, attributed to broader market conditions affecting small-cap biotech firms.
• Funding Challenges: The need for substantial capital to fund the Phase III trial poses a risk, especially in the current financing environment.
• Investor Sentiment: Concerns about the lack of trading activity and volatility due to a limited shareholder base treating their holdings as long-term investments.

5. Notable Q&A Insights

• CENDIFOX Trial Data: No precise timeline for the next data cut due to academic control over the study.
• GBM Trial Enrollment: Approximately two-thirds of the 30 patients targeted have been enrolled, progressing as planned.
• Cash Flow Projections: Current projections do not include assumptions for Phase III trial expenses.
• Investor Perception: Management acknowledged that investors may not fully appreciate the value and potential of certepetide, emphasizing ongoing efforts to secure partnerships for funding.
• Future Licensing Strategy: The company is actively pursuing additional licensing opportunities based on recent successes, utilizing internal resources rather than external consultants.

Overall, Lisata Therapeutics is navigating a challenging market while advancing its clinical programs and seeking strategic partnerships to fund future growth.